CareDx Posts 24 Percent Q2 Revenue Growth | GenomeWeb

NEW YORK (GenomeWeb) – CareDx reported after the close of the market Wednesday that its second quarter revenues increased 24 percent year over year on higher testing revenue and volume.

The Brisbane, Calif.-based molecular diagnostics firm brought in total revenues of $6.8 million for the three months ended June 30, compared to $5.5 million for the second quarter of 2013. Its testing revenue jumped to $6.7 million from $5.5 million, while its collaboration and license revenue declined to $66,000 from $124,000 year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.